- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.09. | HeartSciences Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 15.09. | Heart Test Laboratories GAAP EPS of -$0.86 misses by $0.11 | 8 | Seeking Alpha | ||
| 15.09. | HeartSciences Inc.: HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update | 221 | GlobeNewswire (Europe) | Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026 Commercial effort... ► Artikel lesen | |
| 14.09. | HeartSciences Inc. - 10-Q, Quarterly Report | 7 | SEC Filings | ||
| 25.08. | HeartSciences Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| HEARTSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.08. | HeartSciences Inc.: Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration | 317 | GlobeNewswire (Europe) | Fortitude purchased approximately $1,000,000 of HeartSciences' shares of common stock at $2.43 per share, a 22% premium to the closing price on the purchase dateThe exchange ratio under the merger... ► Artikel lesen | |
| 18.08. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | HeartSciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | HeartSciences Inc.: HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results | 275 | GlobeNewswire (Europe) | Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company's shareholders Fiscal 2026 saw the full commercial launch... ► Artikel lesen | |
| 23.07. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | HeartSciences Inc.: HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 23.07. | HeartSciences Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.07. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Fortitude And HeartSciences Announce Business Combination | 1 | pulse2.com | ||
| 23.06. | HeartSciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.06. | Fortitude Mining to merge with HeartSciences in all-stock deal | 2 | Investing.com | ||
| 23.06. | Fortitude Mining Holdings, Inc. and HeartSciences Inc. Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets | 310 | Business Wire | FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (Nasdaq: HSCS) ("HeartSciences")... ► Artikel lesen | |
| 11.06. | HeartSciences Inc.: European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents | 293 | GlobeNewswire (Europe) | Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing... ► Artikel lesen | |
| 02.06. | HeartSciences Inc.: HeartSciences Launches MyoVista Insights Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm | 1 | GlobeNewswire (USA) | ||
| 19.05. | HeartSciences signs North Shore Health for MyoVista platform | 1 | Investing.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,498 | -0,97 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,069 | +7,79 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| CERENOME | 1,652 | +1,35 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | +4,57 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 15,300 | +4,08 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,095 | +1,39 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| QUIDELORTHO | 9,630 | +0,63 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,500 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 6,990 | 0,00 % | Lifeward Ltd.: Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer | HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,990 | -2,21 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 8,700 | -1,14 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,020 | +2,00 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen | |
| NANO-X IMAGING | 0,734 | +0,27 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMUNON | 1,230 | +0,82 % | IMUNON-Studie zu Eierstockkrebs wird nach Sicherheitsprüfung fortgesetzt |
HEARTSCIENCES INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 4,585 Euro und damit -0,54 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEARTSCIENCES INC finden Sie auf Wallstreet Online.